Efficacy of hyperthermic intraperitoneal chemotherapy in patients with epithelial ovarian cancer: a meta-analysis

References

• van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378:230–240.
   PubMed Web of Science ®Google Scholar
• Huo YR, Richards A, Liauw W, et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: a systematic review and meta-analysis. Eur J Surg Oncol. 2015;41:1578–1589.
   PubMed Web of Science ®Google Scholar
• NCCN. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018:MS3-9. Available from: https://www.nccn.org/.
   Google Scholar
• Denny L, Quinn M. FIGO cancer report 2015. Int J Gynaecol Obstet. 2015;131:S111.
   PubMed Web of Science ®Google Scholar
• Markman M. Intraperitoneal chemotherapy in the management of malignant disease. Expert Rev Anticancer Ther. 2001;1:142–148.
   PubMedGoogle Scholar
• Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34–43.
   PubMed Web of Science ®Google Scholar
• Wright AA, Cronin A, Milne DE, et al. Use and effectiveness of intraperitoneal chemotherapy for treatment of ovarian cancer. JCO. 2015;33:2841–2847.
   PubMed Web of Science ®Google Scholar
• Tewari D, Java JJ, Salani R, et al. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. JCO. 2015;33:1460–1466.
   PubMed Web of Science ®Google Scholar
• van Driel WJ, Lok CA, Verwaal V, et al. The role of hyperthermic intraperitoneal intraoperative chemotherapy in ovarian cancer. Curr Treat Options Oncol. 2015;16:14.
   PubMed Web of Science ®Google Scholar
• Cowan RA, O’Cearbhaill RE, Zivanovic O, et al. Current status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) clinical trials in ovarian cancer. Int J Hyperthermia. 2017;33:548–553.
   PubMed Web of Science ®Google Scholar
• Bhatt A, Glehen O. The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (hipec) in ovarian cancer: a review. Indian J Surg Oncol. 2016;7:188–197.
   PubMed Web of Science ®Google Scholar
• Los G, Sminia P, Wondergem J, et al. Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats. Eur J Cancer. 1991;27:472–477.
   PubMed Web of Science ®Google Scholar
• Los G, van Vugt MJ, den Engelse L, et al. Effects of temperature on the interaction of cisplatin and carboplatin with cellular DNA. Biochem Pharmacol. 1993;46:1229–1237.
   PubMed Web of Science ®Google Scholar
• Los G, van Vugt MJ, Pinedo HM. Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin. Br J Cancer. 1994;69:235–241.
   PubMed Web of Science ®Google Scholar
• Hettinga JV, Konings AW, Kampinga HH. Reduction of cellular cisplatin resistance by hyperthermia – a review. Int J Hyperthermia. 1997;13:439–457.
   PubMed Web of Science ®Google Scholar
• Reed E, Parker RJ, Gill I, et al. Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies. Cancer Res. 1993;53:3694–3699.
   PubMed Web of Science ®Google Scholar
• Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. JCO. 2003;21:3737–3743.
   PubMed Web of Science ®Google Scholar
• Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. JCO. 2012;30:2449–2456.
   PubMed Web of Science ®Google Scholar
• Helm JH, Miura JT, Glenn JA, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol. 2015;22:1686–1693.
   PubMed Web of Science ®Google Scholar
• Esquivel J. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: survival outcomes and patient selection. J Gastrointest Oncol. 2016;7:72–78.
   PubMed Web of Science ®Google Scholar
• Seretis C, Shariff U, Raju T, et al. Proceedings of the 9th International Congress on Peritoneal Surface Malignancies, October 9th–11th 2014, Amsterdam. J Buon. 2015;20:346–347.
   PubMed Web of Science ®Google Scholar
• Cascales PA, Gil J, Galindo PJ, et al. Heterogeneity in patients and methods. A problem for hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol. 2011;158:361–362.
   PubMed Web of Science ®Google Scholar
• Chiva LM, Gonzalez-Martin A. A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer. Gynecol Oncol. 2015;136:130–135.
   PubMed Web of Science ®Google Scholar
• du Bois A, Reuss A, Pujade-Lauraine E, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009;115:1234–1244.
   PubMed Web of Science ®Google Scholar
• Chi DS, Musa F, Dao F, et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol. 2012;124:10–14.
   PubMed Web of Science ®Google Scholar
• Harter P, Beutel B, Alesina PF, et al. Prognostic and predictive value of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) score in surgery for recurrent ovarian cancer. Gynecol Oncol. 2014;132:537–541.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol. 1999;6:727–731.
   PubMed Web of Science ®Google Scholar
• Vernaccini N, Stefano B, Bertozzi S, et al. Surgical cytoreduction and hyperthermic intraperitoneal chemotherapy in patients affected by recurrent or persistent peritoneal carcinomatosis form epithelial ovarian cancer with high peritoneal cancer index values: our single center experience. Euro J Surg Oncol. 2016;42:S215.
   Google Scholar
• Wu Y, Chen L, Zhao Y, et al. Efficacy and safety of hyperthermic intraoperative intraperitoneal chemotherapy with Paclitaxel and Cisplatin in the treatment of ovarian cancer. Anti-Tumor Pharmacy. 2016;6:291–295.
   Google Scholar
• Mendivil AA, Rettenmaier MA, Abaid LN, et al. Consolidation hyperthermic intraperitoneal chemotherapy for the treatment of advanced stage ovarian carcinoma: a 3 year experience. Cancer Chemother Pharmacol. 2017;80:405–410.
   PubMed Web of Science ®Google Scholar
• Baiocchi G, Ferreira FO, Mantoan H, et al. Hyperthermic intraperitoneal chemotherapy after secondary cytoreduction in epithelial ovarian cancer: a single-center comparative analysis. Ann Surg Oncol. 2016;23:1294–1301.
   PubMed Web of Science ®Google Scholar
• Spiliotis J, Halkia E, Lianos E, et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2015;22:1570–1575.
   PubMed Web of Science ®Google Scholar
• Cascales-Campos PA, Gil J, Feliciangeli E, et al. The role of hyperthermic intraperitoneal chemotherapy using paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreduction. Ann Surg Oncol. 2015;22:987–993.
   PubMed Web of Science ®Google Scholar
• Le Brun JF, Campion L, Berton-Rigaud D, et al. Survival benefit of hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer: a multi-institutional case control study. Ann Surg Oncol. 2014;21:3621–3627.
   PubMed Web of Science ®Google Scholar
• Cascales-Campos PA, Gil J, Gil E, et al. Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage IIIC/IV ovarian cancer. Ann Surg Oncol. 2014;21:2383–2389.
   PubMed Web of Science ®Google Scholar
• Konigsrainer I, Horvath P, Struller F, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in recurrent epithelial ovarian cancer with peritoneal metastases: a single centre experience. Langenbecks Arch Surg. 2014;399:589–594.
   PubMed Web of Science ®Google Scholar
• Fagotti A, Costantini B, Petrillo M, et al. Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case-control study on survival in patients with two year follow-up. Gynecol Oncol. 2012;127:502–505.
   PubMed Web of Science ®Google Scholar
• Warschkow R, Tarantino I, Lange J, et al. Does hyperthermic intraoperative chemotherapy lead to improved outcomes in patients with ovarian cancer? A single center cohort study in 111 consecutive patients. Patient Saf Surg. 2012;6:12.
   PubMedGoogle Scholar
• Kim JH, Lee JM, Ryu KS, et al. Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer. J Surg Oncol. 2010;101:149–155.
   PubMed Web of Science ®Google Scholar
• Munoz-Casares FC, Rufian S, Rubio MJ, et al. The role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer. Clin Transl Oncol. 2009;11:753–759.
   PubMed Web of Science ®Google Scholar
• Gori J, Castano R, Toziano M, et al. Intraperitoneal hyperthermic chemotherapy in ovarian cancer. Int J Gynecol Cancer. 2005;15:233–239.
   PubMed Web of Science ®Google Scholar
• Ryu KS, Kim JH, Ko HS, et al. Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer. Gynecol Oncol. 2004;94:325–332.
   PubMed Web of Science ®Google Scholar
• Safra T, Grisaru D, Inbar M, et al. Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression-free survival, especially in BRCA-positive patients- a case-control study. J Surg Oncol. 2014;110:661–665.
   PubMed Web of Science ®Google Scholar
• Spiliotis J, Halkia E, de Bree E. Treatment of peritoneal surface malignancies with hyperthermic intraperitoneal chemotherapy-current perspectives. Curr Oncol. 2016;23:e266–275.
   PubMed Web of Science ®Google Scholar
• Chua TC, Esquivel J, Pelz JO, et al. Summary of current therapeutic options for peritoneal metastases from colorectal cancer. J Surg Oncol. 2013;107:566–573.
   PubMed Web of Science ®Google Scholar
• Vanounou T, Garfinkle R. Evaluation of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin in the era of value-based medicine. Ann Surg Oncol. 2016;23:2556–2561.
   PubMed Web of Science ®Google Scholar
• Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol. 2009;112:265–274.
   PubMed Web of Science ®Google Scholar
• Munkarah AR, Coleman RL. Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecol Oncol. 2004;95:273–280.
   PubMed Web of Science ®Google Scholar
• Harter P, Du Bois A, Hahmann M, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006;13:1702–1710.
   PubMed Web of Science ®Google Scholar
• Didelot C, Lanneau D, Brunet M, et al. Anti-cancer therapeutic approaches based on intracellular and extracellular heat shock proteins. CMC. 2007;14:2839–2847.
   PubMed Web of Science ®Google Scholar
• Hegyi G, Szigeti GP, Szasz A. Hyperthermia versus oncothermia: cellular effects in complementary cancer therapy. Evid Based Complement Alternat Med. 2013;2013:672873.
   PubMed Web of Science ®Google Scholar
• Harter P, Reuss A, Sehouli J, et al. Brief report about the role of hyperthermic intraperitoneal chemotherapy in a prospective randomized phase 3 study in recurrent ovarian cancer from Spiliotis et al. Int J Gynecol Cancer. 2017;27:246–247.
   PubMed Web of Science ®Google Scholar
• Hotouras A, Desai D, Bhan C, et al. Heated intraperitoneal chemotherapy (HIPEC) for patients with recurrent ovarian cancer: a systematic literature review. Int J Gynecol Cancer. 2016;26:661–670.
   PubMed Web of Science ®Google Scholar
• Carteni G, Manegold C, Garcia GM, et al. Malignant peritoneal mesothelioma-results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer. 2009;64:211–218.
   PubMed Web of Science ®Google Scholar